Bharat Biotech’s vaccine candidate approved for use in clinical trial mode.
India’s first indigenously developed COVID-19 vaccine, Covaxin, has been recommended for “restricted use in emergency situation, subject to multiple regulatory conditionalties” by the Subject Expert Committee (SEC) of Central Drugs Standard Control Organisation (CDSCO), here on Saturday. The Drugs Controller General (DCGI) will take a final call on approving rollout of the vaccine in the country.
The recommendation was made following a two-day meeting which earlier saw the panel sending Covishield, the vaccine developed by AstraZeneca and Oxford University, and manufactured by Pune’s Serum Institute of India (SII) for DCGI approval on Friday.
Coronavirus | ‘Covaxin Phase-III trials nearing 20k volunteers’
The Health Ministry in its statement said the SEC has made three recommendations for the consideration and final decision of the Drugs Controller General of India (DGCI). This includes grant…
